DCGI approves Covaxin for kids for 2-18 age group

The Subject Expert Committee (SEC) on Tuesday approved the use of Bharat Biotech’s Covaxin for the children for the age group of 2-18 years.

The Subject Expert Committee (SEC) on Tuesday approved the use of Bharat Biotech’s Covaxin for the children for the age group of 2-18 years. 

Hyderabad based Bharat Biotech completed Phase-2 and Phase-3 trials of Covaxin in September on children below 18 years of age. The company had submitted the trial data to the Drugs and Comptroller General of India (DCGI) earlier this month. 

Covaxin is the second Covid-19 vaccine to be approved for emergency use among children in India after Zydus Healthcare’s ZyCoV-D, meant for children above 12 years of age.

According to one of the senior official, “As per the data that the company submitted, the vaccine has been found to be safe and efficacious in children. The experts were of the opinion that it should be allowed for use in children.

According to the Union Health Ministry, India on Tuesday recorded 14,313 fresh Covid cases in the last 24 hours, the lowest in the past 224 days. Whereas, 181 fatalities were reported in the last 24 hours, the death toll climbed to 4,50,963. India’s recovery rate stands at 98.04 per cent which is currently at its highest peak since March 2020.

Sponsored Content